Médecins Dr. Anne de la Rochefordière

Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome

DOI: 10.1016/j.ebiom.2019.03.069

Pelvic insufficiency fracture (PIF) incidence in patients treated with intensity-modulated radiation therapy (IMRT) for gynaecological or anal cancer: single-institution experience and review of the literature.

DOI: 10.1259/bjr.20160885

Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection.

DOI: 10.1038/bjc.2016.144

PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients.

DOI: 10.1158/1078-0432.CCR-14-2368

Reasons of not having breast reconstruction: a historical cohort of 1937 breast cancer patients undergoing mastectomy.

DOI: 10.1186/2193-1801-2-325

Chemotherapy in the treatment of anal canal carcinoma.

DOI: 10.1016/j.dld.2012.04.013

Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome.

DOI: 10.1007/s10689-012-9539-1

Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients.

DOI: 10.1371/journal.pone.0043393

Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute

DOI: 10.1155/2010/214919

Implications of genetic risk factors in breast cancer: culprit genes and associated malignancies